ITGAV and prostate carcinoma: CD51 is expressed at high levels in prostate cancer patients and correlates with poor prognosis; CD51+ prostate cancer cells have self-renewal capacity and its expression is required for prostate cancer stem cell-related properties and increases metastatic and drug-resistant properties [567].